GRCE Valuation

Grace Therapeutics, Inc

Add to Watchlist

Advanced Chart

3.120

+0.06(1.961%)1D

Overview
Forecast
Valuation
Earnings

GRCE Relative Valuation

GRCE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, GRCE is overvalued; if below, it's undervalued.

Historical Valuation

Grace Therapeutics, Inc (GRCE) is now in the Fair zone, suggesting that its current forward PS ratio of 47.46 is considered Fairly compared with the five-year average of -3.14. The fair price of Grace Therapeutics, Inc (GRCE) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：3.06

Fair

-3.22

Trailing

Forward

-1.18

EV/EBITDA

Grace Therapeutics, Inc. (GRCE) has a current EV/EBITDA of -1.18. The 5-year average EV/EBITDA is -1.23. The thresholds are as follows: Strongly Undervalued below -1.80, Undervalued between -1.80 and -1.52, Fairly Valued between -0.95 and -1.52, Overvalued between -0.95 and -0.67, and Strongly Overvalued above -0.67. The current Forward EV/EBITDA of -1.18 falls within the Historic Trend Line -Fairly Valued range.

-1.40

EV/EBIT

Grace Therapeutics, Inc. (GRCE) has a current EV/EBIT of -1.40. The 5-year average EV/EBIT is -1.37. The thresholds are as follows: Strongly Undervalued below -2.03, Undervalued between -2.03 and -1.70, Fairly Valued between -1.03 and -1.70, Overvalued between -1.03 and -0.70, and Strongly Overvalued above -0.70. The current Forward EV/EBIT of -1.40 falls within the Historic Trend Line -Fairly Valued range.

47.46

Grace Therapeutics, Inc. (GRCE) has a current PS of 47.46. The 5-year average PS is 10.49. The thresholds are as follows: Strongly Undervalued below -29.49, Undervalued between -29.49 and -9.50, Fairly Valued between 30.48 and -9.50, Overvalued between 30.48 and 50.47, and Strongly Overvalued above 50.47. The current Forward PS of 47.46 falls within the Overvalued range.

-2.05

P/OCF

Grace Therapeutics, Inc. (GRCE) has a current P/OCF of -2.05. The 5-year average P/OCF is -2.22. The thresholds are as follows: Strongly Undervalued below -2.78, Undervalued between -2.78 and -2.50, Fairly Valued between -1.94 and -2.50, Overvalued between -1.94 and -1.66, and Strongly Overvalued above -1.66. The current Forward P/OCF of -2.05 falls within the Historic Trend Line -Fairly Valued range.

-2.05

P/FCF

Grace Therapeutics, Inc. (GRCE) has a current P/FCF of -2.05. The 5-year average P/FCF is -2.22. The thresholds are as follows: Strongly Undervalued below -2.78, Undervalued between -2.78 and -2.50, Fairly Valued between -1.94 and -2.50, Overvalued between -1.94 and -1.66, and Strongly Overvalued above -1.66. The current Forward P/FCF of -2.05 falls within the Historic Trend Line -Fairly Valued range.

Grace Therapeutics, Inc (GRCE) has a current Price-to-Book (P/B) ratio of 0.67. Compared to its 3-year average P/B ratio of 0.60 , the current P/B ratio is approximately 10.46% higher. Relative to its 5-year average P/B ratio of 0.60, the current P/B ratio is about 10.46% higher. Grace Therapeutics, Inc (GRCE) has a Forward Free Cash Flow (FCF) yield of approximately -30.68%. Compared to its 3-year average FCF yield of -36.07%, the current FCF yield is approximately -14.95% lower. Relative to its 5-year average FCF yield of -36.07% , the current FCF yield is about -14.95% lower.

0.67

P/B

Median3y

0.60

Median5y

0.60

-30.68

FCF Yield

Median3y

-36.07

Median5y

-36.07

Competitors Valuation Multiple

The average P/S ratio for GRCE's competitors is 9.22, providing a benchmark for relative valuation. Grace Therapeutics, Inc Corp (GRCE) exhibits a P/S ratio of 47.46, which is 414.94% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

GRCE.O

Grace Therapeutics, Inc

Telomir Pharmaceuticals Inc

Loss

42.93M

BRNS.O

Barinthus Biotherapeutics PLC

Loss

43.57M

PSTV.O

Plus Therapeutics Inc

Verrica Pharmaceuticals Inc

Tempest Therapeutics Inc

Loss

42.54M

Performance Decomposition

Market capitalization of GRCE increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of GRCE in the past 1 year is driven by Unknown.